Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia

Jiang, Lei; Lindpaintner, Klaus; Li, H.-F.; Gu, Nannan; Langen, Hanno; Fountoulakis, Michael

doi:10.1007/s00726-003-0356-6

Cited by 94 publications

(65 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…146 Interestingly, Thomas et al 147 also reported increased levels of apolipoprotein D in the central nervous system and a decrease in serum of schizophrenia patients, which could imply a compensatory role of apoD for a neuropathological process that is initiated by systemic lipid metabolism insufficiencies. Jiang et al 148 found apolipoprotein A-IV to be downregulated in cerebrospinal fluid of schizophrenia patients. Furthermore, clozapine treatment of rats has been found to alter apoD gene expression.…”

Section: Apolipoproteinsmentioning

confidence: 99%

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum

et al. 2009

View full text Add to dashboard Cite

Section: Apolipoproteinsmentioning

confidence: 99%

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum

et al. 2009

View full text Add to dashboard Cite

“…16 While the literature shows pathology in the structure, function and circuitry of the ACC in schizophrenia, this brain region is not well characterized in the disease state. Proteomics, with the ability to investigate the translation of genomic information together with co-and post-translational modifications, 17 offers an approach to studying the global changes in protein expression and modification caused by neuropathologies such as Alzheimer's Disease (AD), Down Syndrome (DS) and schizophrenia. Previous findings of proteomic investigations into schizophrenia include various proteins associated with metabolism and oxidative stress to be differentially expressed in the prefrontal cortex (PFC) in the disease state relative to controls, 18 proteins previously implicated in schizophrenia as well as some novel proteins to be altered in the frontal cortex, 19 and four of 18 altered proteins in the schizophrenia hippocampus mapping to chromosome 6q.…”

Section: Introductionmentioning

confidence: 99%

“…Previous findings of proteomic investigations into schizophrenia include various proteins associated with metabolism and oxidative stress to be differentially expressed in the prefrontal cortex (PFC) in the disease state relative to controls, 18 proteins previously implicated in schizophrenia as well as some novel proteins to be altered in the frontal cortex, 19 and four of 18 altered proteins in the schizophrenia hippocampus mapping to chromosome 6q. 20 In addition, a proteomic study investigating the cerebrospinal fluid (CSF) in schizophrenia identified 54 different gene products, 17 leading to new and refined hypotheses into the molecular mechanisms underlying this disease.…”

Section: Introductionmentioning

confidence: 99%

A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia

et al. 2006

View full text Add to dashboard Cite

The Anterior Cingulate Cortex (ACC, Brodmans Area 24) is implicated in the pathogenesis of schizophrenia due to its normal functions and connectivity together with reports of structural, morphological and neurotransmitter aberrations within this brain area in the disease state. Two-dimensional gel electrophoresis (2DE) was employed to scan and compare the ACC gray matter proteomes between schizophrenia (n = 10) and control (n = 10) post-mortem human tissue. This proteomic approach has detected 42 protein spots with altered levels in the schizophrenia cohort, which to our knowledge is the first proteomic analysis of the ACC in schizophrenia. Thirty nine of these proteins were subsequently identified using mass spectrometry and functionally classified into metabolism and oxidative stress, cytoskeletal, synaptic, signalling, trafficking and glial-specific groups. Some of the identified proteins have previously been implicated in the disease pathogenesis and some offer new insights into schizophrenia. Investigating these proteins, the genes encoding these proteins, their functions and interactions may shed light on the molecular mechanisms underlying the heterogeneous symptoms characteristic of schizophrenia.

show abstract

“…The levels of several CSF proteins were deranged as well, like apolipoprotein A4 [64], complement C3, insulin receptorrelated protein, and vitamin D-binding protein [116]. In a rat model of neuropathic pain, the Ca-binding proteins calmodulin and calretinin as well as protein-tyrosin phosphatase A, Ras-related protein RAB-15, and stress-activated protein kinase JNK3 showed lower levels.…”

Section: Signal Transduction Proteinsmentioning

confidence: 99%

“…Functional imaging and postmortem studies in the brain of patients with these diseases have revealed histological, functional, and neurochemical abnormalities in the anterior cingulated cortex [58][59][60][61][62]. Brain and CSF from patients with schizophrenia as well as brain from animal models of the disorder have been studied by proteomics approaches and a series of proteins possibly related with the disease have been identified [55,[63][64][65][66].…”

Section: Schizophrenia Bipolar Disorder Depressionmentioning

confidence: 99%

Proteomics‐driven progress in neurodegeneration research

Fountoulakis

Κοσσίδα

2006

Electrophoresis

View full text Add to dashboard Cite

Proteomics-driven progress in neurodegeneration researchProteomics technologies have been widely used in the investigation of neurodegenerative and psychiatric disorders, and in particular in the detection of differences between healthy individuals and patients suffering from such diseases. Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. 2-DE followed by MALDI-TOF-MS has been mainly applied as this proteomics approach provides the possibility of convenient quantification of protein levels and detection of post-translational modifications. About 330 unique proteins with deranged levels and modifications have been detected by proteomics approaches to be related to neurodegeneration and psychiatric disorders. They are mainly involved in metabolism pathways, cytoskeleton formation, signal transduction, guidance, detoxification, transport, and conformational changes. In this article, we provide a summary of the major contributions of proteomics technologies in the study of neurodegenerative and psychiatric diseases, in particular, in the detection of changes in protein levels and modifications related to these disorders. IntroductionNeurodegeneration is a major hallmark of a series of genetic and acquired disorders of the central nervous system (CNS), like Alzheimer's disease (AD), Down syndrome (DS), Pick's disease, Creutzfeldt-Jakob disease (CJD), and Parkinson's disease, which result in severe cognitive and motor deficits. A common characteristic of these diseases is that they are multifactorial.Their molecular basis is unknown and individual biomarkers are not reliable. Genomics and proteomics approaches have been applied to obtain a better understanding of neurodegeneration and psychiatric disorders. Genomics has been used to map and identify genes that are mutated in a wide variety of such disorders, like presenilins in AD. Next to genomics, which only provides a partial view of the biological problem, proteomics is widely used in clinical diagnosis as well and many changes in protein levels associated with specific diseases have been identified [1,2].Proteomics is a technology-driven science that studies the proteins of the various biological systems, their structures, interactions, post-translational modifications, and in particular the changes in their levels and modifications, which are the result of specific diseases or are induced by external factors.

show abstract

Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia

Cited by 94 publications

References 29 publications

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum

A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia

Proteomics‐driven progress in neurodegeneration research

Contact Info

Product

Resources

About